Lenalidomide capsules | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Others

Brand
Revlimid
Company
Bristol-Myers Squibb Pharma EEIG (EU authorization holder)
Medicine type
Chemical medicine
Therapeutic area
Oncology
Indications recorded in the public source
European Union source summary: For adult multiple myeloma as maintenance after autologous stem-cell transplantation, in specified combinations for untreated transplant-ineligible disease, or with dexamethasone after at least one prior therapy. Other uses include transfusion-dependent anemia from low- or intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q when alternatives are inadequate; relapsed or refractory mantle-cell lymphoma; and previously treated grade 1-3a follicular lymphoma with rituximab.
Indication source and scope
European Union product information accessed 2 November 2026; exact revision date not separately extracted.. Selected overseas indications; does not establish the Chinese approved scope.
Prescribing-information limitations
Overseas official prescribing information linked; a complete current Chinese label has not been verified.
China availability status
Chinese approval, current approved indications and continuous market availability have not been independently verified in this English-source review.
Overseas status
See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
Insurance classification
Not yet verified
Insurance edition
Chinese national insurance review pending
Insurance verification notes
No reimbursement determination was made for this addition; missing information is not proof of exclusion.

Sources

Evidence reviewed:

Open the interactive record, public price references and discussions